Skip to main content

Bristol Myers Squibb · Healthcare & Pharma

In AI answers, Bristol Myers Squibb is a supporting name in failed-trial and drug-pricing stories

Across the sampled answers, Bristol Myers Squibb turns up in lists about phase 3 setbacks, congressional pricing hearings and executive pay policy. The press coverage in the same period is about its stock and its multiple myeloma trial data.

Measured September 29, 2026ChatGPT, Claude, Gemini, Perplexity and GrokCheck your own brand →

In AI answers

Visibility

6%

Share of answers that named Bristol Myers Squibb, with a 95% range of 5–8%. Measured September 29, 2026 · 5 assistants · 1,250 answers.

Answers naming it

78 / 1,250

Position by visibility

#11 of 15

In this snapshot only

In the press

News mentions

9,333

PeakMetrics news index, last 30 days.

Bristol Myers Squibb in the headline

1,076

Rank by press volume

#10 of 15

Within this sector

Named in 42 of 250 questions, the 12 most-named shown

Question
Which pharma companies are known for layoffs and unstable jobs?Named by: ChatGPT, Claude, Gemini, Perplexity, Grok
Which pharma companies are investing the most in cell and gene therapy manufacturing?Named by: ChatGPT, Claude, Gemini, Perplexity, Grok
I'm a journalist looking into drug pricing. Which companies have testified before Congress about list prices and rebates?Named by: Claude, Gemini, Perplexity, Grok
What are the top-selling prescription drugs and which companies make them?Named by: Claude, Gemini, Perplexity, Grok
Which drug makers have the strongest oncology research pipelines right now?Named by: ChatGPT, Claude, Perplexity, Grok
Which pharma companies have faced the most litigation?Named by: ChatGPT, Perplexity, Grok
Which pharma companies have pledged net-zero emissions, and which of them are actually on track?Named by: ChatGPT, Perplexity, Grok
Are there drug makers that tie executive pay to sustainability or health-equity targets?Named by: ChatGPT, Perplexity, Grok
Which drug manufacturers offer the most generous patient assistance programs for people who can't afford their medications?Named by: ChatGPT, Perplexity, Grok
Which drug makers have the worst reputation on pricing?Named by: ChatGPT, Grok
Which healthcare companies are most committed to patient access?Named by: Perplexity, Grok
As an investor, which pharma stocks carry the most legal and regulatory risk right now?Named by: Claude, Grok

and 30 more questions whose answers named Bristol Myers Squibb.

The evidence

One snapshot, measured September 29, 2026. These figures come from one quarterly run of 1,250 answers (95% range 5–8%), not a ranking or a trend. The questions never named Bristol Myers Squibb.

How the answers frame Bristol Myers Squibb

This snapshot covers 250 benchmark questions across ChatGPT, Claude, Gemini, Perplexity and Grok, measured on 2026-09-29. None of the questions named a brand. Bristol Myers Squibb was named in 78 of 1,250 answers. Grok accounted for the most appearances (34 of 250), followed by Perplexity (16), ChatGPT (12), Claude (10) and Gemini (6). Seven stored answers are supplied here as a sample of those appearances.

In those seven, the company is usually one name in a list. Claude's answer on phase 3 failures grouped it with Johnson & Johnson on the halted milvexian trial. Grok's answer on the same question named it among several large drugmakers. Gemini's answer on drug pricing listed it among the companies that testified before Congress in 2019, and again for a February 2024 Senate HELP hearing and a September 2020 House hearing. ChatGPT included it in a list of oncology pipeline names, but with no separate account of what it does.

The one answer that describes a company practice is Perplexity's, on executive pay. It attributes to Bristol Myers Squibb a Sustainability Scorecard in its senior executive incentive program. ChatGPT also named the company among examples of drug makers linking pay to sustainability targets. The credited-for tags are thin. Five mentions were tagged "Not Substantive" and one "Sustainability & Ethics."

By question intent, visibility in this snapshot was highest on leadership (12%), employer (11%) and pricing transparency (10%). It was 0% on value and service questions and low on reliability, trust and safety.

The Phase III trial of Milvexian (Factor XIa inhibitor) was halted early due to a lack of therapeutic efficacy, with J&J and BMS terminating the study which intended to enroll 16,000 patients.
Claude, answering “I'm a journalist writing about drug efficacy. Which manufacturers have had the most drugs that failed in phase 3 trials recently?”

What the press is saying

PeakMetrics' news index logged 9,333 mentions of Bristol Myers Squibb over the last 30 days. Of those, 1,076 had the company in the headline.

The recent headlines fall into three groups. The first is stock performance, such as "Are Medical Stocks Lagging Bristol Myers Squibb (BMY) This Year?" from nasdaq.com. The second is clinical data: the company announced the first presentation of phase 3 EXCALIBER-RRMM results for ZENBEXUS (iberdomide) with daratumumab in relapsed or refractory multiple myeloma, and that release was syndicated across several sites. The third is a personnel item. BioMarin announced that Robert Plenge, Bristol Myers Squibb's Chief Research Officer, is joining its board.

…says its senior executives’ annual incentive program uses a Sustainability Scorecard, including progress on patient-access goals in low- and middle-income countries.
Perplexity, answering “Are there drug makers that tie executive pay to sustainability or health-equity targets?”

The gap

The press storylines are market performance and a pipeline data release. The AI answers in this sample carry a different set of associations: a shared phase 3 failure, past pricing hearings, and a pay-linked sustainability scorecard. The multiple myeloma trial results in the headlines do not appear in any of the seven sampled answers.

Press volume also does not map neatly onto answer visibility. Amgen and Merck each have more than twice Bristol Myers Squibb's 30-day news mentions, yet Bristol Myers Squibb is named in more answers than Amgen and fewer than Merck. Johnson & Johnson (192 of 1,250 answers) and Pfizer (174) are named far more often than Bristol Myers Squibb (78), on news volumes that are also higher. Neither press volume nor answer counts here should be read as a fixed ranking.

What to watch

First, the milvexian association. Claude's answer places the company inside a phase 3 failure narrative on a question from a journalist persona. Comms teams can check whether the same framing recurs when that question is asked again, since live answers vary between runs.

Second, the pricing history. Gemini's answer draws on hearings from 2019, 2020 and 2024, so older testimony can shape how the company is described on current pricing questions.

Third, the sustainability scorecard. It is the only company-specific practice in the sample, and Perplexity's answer says the company itself reports it. Whether current company material on that practice and on the multiple myeloma data reaches the answers is worth tracking.

This is a single snapshot of seven sampled answers. It is a starting point for benchmarking, not a trend.

The evidence

Where Bristol Myers Squibb appeared, and what it was credited for.

Per-provider split

The same answers split by assistant, each with its 95% range. Where two assistants' ranges overlap, the difference between them may be noise.

  1. ChatGPT
    5%3–8%
  2. Claude
    4%2–7%
  3. Gemini
    2%1–5%
  4. Perplexity
    6%4–10%
  5. Grok
    14%10–18%

Appeared in

The 12 questions whose answers named Bristol Myers Squibb most often, with each assistant that named it. 42 questions named it in all. The questions did not mention the brand.

  • Which pharma companies are known for layoffs and unstable jobs?ChatGPTClaudeGeminiPerplexityGrok
  • Which pharma companies are investing the most in cell and gene therapy manufacturing?ChatGPTClaudeGeminiPerplexityGrok
  • I'm a journalist looking into drug pricing. Which companies have testified before Congress about list prices and rebates?ClaudeGeminiPerplexityGrok
  • What are the top-selling prescription drugs and which companies make them?ClaudeGeminiPerplexityGrok
  • Which drug makers have the strongest oncology research pipelines right now?ChatGPTClaudePerplexityGrok
  • Which pharma companies have faced the most litigation?ChatGPTPerplexityGrok
  • Which pharma companies have pledged net-zero emissions, and which of them are actually on track?ChatGPTPerplexityGrok
  • Are there drug makers that tie executive pay to sustainability or health-equity targets?ChatGPTPerplexityGrok
  • Which drug manufacturers offer the most generous patient assistance programs for people who can't afford their medications?ChatGPTPerplexityGrok
  • Which drug makers have the worst reputation on pricing?ChatGPTGrok
  • Which healthcare companies are most committed to patient access?PerplexityGrok
  • As an investor, which pharma stocks carry the most legal and regulatory risk right now?ClaudeGrok

Visibility by question type

The share of answers to each type of question that named Bristol Myers Squibb, with its 95% range. Each type has fewer answers than the whole run, so its range is wider.

  1. Reliability and quality
    2%1–7%
  2. Trust and reputation
    3%1–9%
  3. Value and price
    0%0–4%
  4. Customer service
    0%0–4%
  5. Safety and security
    2%1–7%
  6. Innovation
    7%4–14%
  7. Leadership and scale
    12%7–20%
  8. Employer and workplace
    11%6–18%
  9. Sustainability and ethics
    9%5–17%
  10. Avoid and risk
    8%4–16%
  11. Coverage and access to care
    9%5–16%
  12. Clinical outcomes and efficacy
    8%4–16%
  13. Pricing practices and transparency
    10%6–17%
Measured September 29, 2026. ChatGPT, Claude, Gemini, Perplexity and Grok. Types with no answers are left out.

What the answers credited it for

The topics the answers tied to Bristol Myers Squibb when they named it, as labeled by a classifier run on this site (a Visibility Driver label, not a customer workspace's Smart Category). It describes what the answer discussed, not whether it was favorable.

  • Not Substantive5 answers
  • Sustainability & Ethics1 answer

Press rank and AI rank

Where Bristol Myers Squibb sits among the 15 healthcare & pharma brands with news data in this snapshot, on each measure. Ranks only: the two measures use different units and time windows.

Rank by AI visibility

#11 of 15

  1. 11

Share of 1,250 answers, measured September 29, 2026.

Rank by news mentions

#10 of 15

  1. 10

PeakMetrics news index, last 30 days.

Mention volume is not comparable across sectors, so both ranks are within this sector.

Recent PeakMetrics headlines

A sample of recent coverage from the PeakMetrics news index, covering the last 30 days. Links open the original article.

How this was measured

Measured September 29, 2026. 250 unbranded questions per sector, asked to ChatGPT, Claude, Gemini, Perplexity and Grok on their product models, with web search on. Refreshed quarterly.

This is a snapshot, not a ranking or a trend: AI answers vary from run to run. It shows whether a brand appeared and which sources were cited, not how favorably it was described. The paid platform tracks favorability daily.

Full method

In an early five-question test, the same brand went from 40% to 30% to 70% visibility across three runs, which is why every figure here is dated and treated as a snapshot.

The questions cover 13 intents, such as reliability, value for money and customer service. A model drafted them, a review pass removed paraphrases and questions that point to one company, and every question was checked so that none names a measured brand. Each was asked once per assistant in run 2026Q4.

Every visibility figure comes with a 95% range (a Wilson interval). Where two brands' ranges overlap, treat them as tied. The figures use all 1,250 answers. The quotes in the story come from a stratified sample of 60 of them, spread across every assistant and intent.

Summarized on September 30, 2026from this snapshot's stored answers. Every quote is checked against the original answer.

← Healthcare & Pharma sector reportCheck your own brand →

Related

Your brand

Run the same unbranded questions for your own category.

Check your own brand

Track how AI answers describe your brand every day.

AI Perceptions follows all 5 providers daily, next to the news and social coverage PeakMetrics already monitors.

Book a Demo